gms | German Medical Science

43. Kongress der Deutschen Gesellschaft für Rheumatologie, 29. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie, 25. Wissenschaftliche Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie

02.-05. September 2015, Bremen

Choosing the right treatment for patients with a severe course of Chronic non-bacterial osteomyelitis (CNO) – pamidronate or TNF-α blockade?

Meeting Abstract

  • Henner Morbach - Universitäts-Kinderklinik, Würzburg
  • Anja Schnabel - Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus der TU Dresden, Pädiatrische Rheumatologie, Dresden
  • Normi Bruck - Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus der TU Dresden, Pädiatrische Rheumatologie, Dresden
  • Annette Holl-Wieden - Universitäts-Kinderklinik, Würzburg
  • Hermann Girschick - Vivantes Klinikum im Friedrichshain, Klinik für Kinder- und Jugendmedizin, Berlin
  • Christian Michael Hedrich - Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, TU Dresden, Dresden

Deutsche Gesellschaft für Rheumatologie. Deutsche Gesellschaft für Orthopädische Rheumatologie. Gesellschaft für Kinder- und Jugendrheumatologie. 43. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 29. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 25. wissenschaftliche Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR). Bremen, 02.-05.09.2015. Düsseldorf: German Medical Science GMS Publishing House; 2015. DocKR.40

doi: 10.3205/15dgrh165, urn:nbn:de:0183-15dgrh1659

Published: September 1, 2015

© 2015 Morbach et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.


Outline

Text

Introduction: Chronic non-bacterial osteomyelitis (CNO) is an inflammatory, non-infectious disorder of the skeletal system with unknown aetiology. Therapeutic options are NSAIDs, steroids and DMARDs (MTX or sulfasalazine). However, a considerable number of patients have a severe disease course and bisphosphonates or TNF-α blockade might be a therapeutic option.

Methods: We performed a multicentre, retrospective chart review of all patients diagnosed with CNO in two Paediatric Rheumatology Centres in the last 10 years and treated with pamidronate and/or TNF-α blockade.

Results: 17 patients were treated with pamidronate and/or TNF-α blockade. Out of these 17 patients 10 were treated with pamidronate alone and showed clinical improvement. Three of the 17 patients were initially treated with TNF-α blockade; two had a positive response, one patient stopped therapy due to minor side effects. Two or one patients were initially treated with pamidonate or TNF-α blockade, respectively, but did not show clinical improvement. Interestingly, switching from pamidronate to TNF-α blockade or vice versa was associated with clinical improvement in these patients. One patient was treated with a combination therapy using pamidronate and TNF-α blockade and showed a good clinical response.

Conclusion: In therapy refractory CNO patients pamidronate and TNF-α blockade reduced disease burden. However, there is evidence that at least some of the patients only benefit from one of the two therapeutic options. Future studies are needed aiming to identify clinical and/or radiological parameters that might guide the decision to the appropriate treatment in an individual patient.